Liraglutide
FDAEvidence
Tier 1 · FDA-approved · Phase 3 RCTs
metabolicweight-lossdiabetes
CYCLE: ongoing · DOSE: 0.6–3.0 mg/day SC
12mo research activity
17 studies indexed
View peptide →All peptides
Kisspeptin
Evidence
Tier 3 · 13 studies (preclinical)
reproductivehormonal
CYCLE: — · DOSE: —
12mo research activity
13 studies indexed
View peptide →BPC-157
Evidence
Tier 3 · 27 studies (preclinical)
healingrecoverytissue-repair
CYCLE: — · DOSE: see notes
12mo research activity
27 studies indexed
View peptide →Hexarelin
Evidence
Tier 3 · 16 studies (preclinical)
gh-releasecardioprotectionrecovery
CYCLE: — · DOSE: —
12mo research activity
16 studies indexed
View peptide →KPV
Evidence
Tier 3 · 15 studies (preclinical)
gut-healthinflammation
CYCLE: — · DOSE: —
12mo research activity
15 studies indexed
View peptide →Thymosin Alpha-1
Evidence
Tier 3 · 29 studies (observational)
immuneinflammation
CYCLE: — · DOSE: —
12mo research activity
29 studies indexed
View peptide →Semax
Evidence
Tier 3 · 11 studies (preclinical)
nootropicneuroprotectionfocus
CYCLE: — · DOSE: —
12mo research activity
11 studies indexed
View peptide →GHK-Cu
Evidence
Tier 3 · 12 studies (preclinical)
skinanti-aginghair
CYCLE: — · DOSE: —
12mo research activity
12 studies indexed
View peptide →MK-677
Evidence
Tier 2 · 14 studies · RCT evidence
gh-releasemuscleappetite
CYCLE: 8w-2y · DOSE: 25mg/day PO
12mo research activity
14 studies indexed
View peptide →Sermorelin
Evidence
Tier 3 · 12 studies (preclinical)
gh-releaseanti-agingsleep
CYCLE: — · DOSE: see notes
12mo research activity
12 studies indexed
View peptide →DSIP
Evidence
Tier 2 · 27 studies · RCT evidence
sleeprecovery
CYCLE: — · DOSE: see notes
12mo research activity
27 studies indexed
View peptide →MOTS-c
Evidence
Tier 3 · 29 studies (preclinical)
metabolicmitochondrialongevity
CYCLE: — · DOSE: —
12mo research activity
29 studies indexed
View peptide →Selank
Evidence
Tier 3 · 19 studies (preclinical)
anxietynootropicfocus
CYCLE: — · DOSE: —
12mo research activity
19 studies indexed
View peptide →Epitalon
Evidence
Tier 3 · 29 studies (preclinical)
longevitysleepanti-aging
CYCLE: — · DOSE: —
12mo research activity
29 studies indexed
View peptide →CJC-1295
Evidence
Tier 3 · 20 studies (preclinical)
gh-releasemusclerecovery
CYCLE: — · DOSE: —
12mo research activity
20 studies indexed
View peptide →Tesamorelin
FDAEvidence
Tier 1 · FDA-approved · Phase 3 RCTs
growth-hormonemetabolicfat-loss
CYCLE: ongoing · DOSE: 2mg/day SC
12mo research activity
19 studies indexed
View peptide →TB-500
Evidence
Tier 3 · 16 studies (preclinical)
healingrecoveryinflammation
CYCLE: — · DOSE: —
12mo research activity
16 studies indexed
View peptide →Semaglutide
FDAEvidence
Tier 1 · FDA-approved · Phase 3 RCTs
metabolicweight-lossfat-loss
CYCLE: — · DOSE: 0.5-1mg/wk SC
12mo research activity
27 studies indexed
View peptide →Ipamorelin
Evidence
Tier 2 · 14 studies · RCT evidence
growth-hormonegh-release
CYCLE: — · DOSE: see notes
12mo research activity
14 studies indexed
View peptide →Tirzepatide
FDAEvidence
Tier 1 · FDA-approved · Phase 3 RCTs
metabolicweight-lossfat-loss
CYCLE: ongoing · DOSE: 5-15mg/wk SC
12mo research activity
28 studies indexed
View peptide →